natgillin/translations-raw huggingface dataset:
Use of an IL-21 antagonist in the manufacture of a medicament for reducing the occurrence or severity of a secondary autoimmune disease in a multiple sclerosis patient who has been or will be treated with a lymphocyte depleting therapy, wherein the secondary autoimmune disease occurs after treatment with the lymphocyte depleting therapy, the method comprising administering the IL-21 antagonist to said patient. 
Uporaba antagonista IL-21 za proizvodnju lijeka za smanjenje pojave ili ozbiljnosti sekundarne autoimune bolesti kod pacijenta s multiplom sklerozom koji je bio liječen ili će biti liječen s terapijom koja oštećuje limfocite, naznačena time da se sekundarna autoimuna bolest javlja poslije tretmana s terapijom koja oštećuje limfocite, te postupak obuhvaća primjenu antagonista II,-21 na navedenog pacijenta.
The co-suspension for use of claim 30, wherein the disease or condition is selected from asthma, COPD, exacerbation of airways hyper reactivity consequent to other drug therapy, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pulmonary hypertension, and pulmonary inflammation and obstruction associated with cystic fibrosis. 
Farmaceutski pripravak za uporabu prema patentnom zahtjevu 23, naznačen time što se plućna bolest ili poremećaj bira od najmanje jednog od astme, KOPB, kroničnog bronhitisa, emfizema, bronhiektazije, alergijskog rinitisa, sinusitisa, plućne vazokonstrikcije, upale, alergija, otežanog disanja, sindroma respiratornog distresa, plućne hipertenzije, upale pluća povezane s cističnom fibrozom, i opstrukcije pluća povezane s cističnom fibrozom.
The pharmaceutical composition of claim 1 comprising a compound of formula IIB, or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein R13 is -(CH2)0-3CR17R18NR20R21, -(CH2)0-3CR17R18NR17C(O)NR20R21 or -(CH2)1-3-R23. 
Farmaceutski sastav prema patentnom zahtjevu 1, koja sadrži spoj formule IIB, ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, pri čemu R13 je -(CH2)0-3CR17R18NR20R21, -(CH2)0-3CR17R18NR17C(O) NR20R21 ili -(CH2)1-3-R23.
The method of claim 6, wherein the detectable marker is selected from a radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound and a chemiluminescent compound. 
Protutijelo ili fragment prema zahtjevu 6, naznačen(0) time, da je protutijelo ili fragment spojen/o na marker koji se može otkriti, pri čemu je taj marker radioizotop, metalni kelator, enzim, fluorescentni spoj, bio-iluminacijski spoj ili kemijsko-iluminacijski spoj.
in which R1A and R3 are each as defined above, this is then reacted in an inert solvent, in the presence of a suitable base, with a compound of the formula (V) X1—R2 (V) 
(IV) gdje R'" i R* su svaki kako je gore definirano, ovo nakon toga reagira u inertnom otapalu, u prisutnosti odgovarajuće baze, sa spojem s formulom (V) X!'.R?
in case said protein molecule is an antibody molecule, it has an increased Fc-mediated cellular cytotoxicity which is at least 2 times higher than the Fc-mediated cellular cytotoxicity of at least one antibody molecule composition from the same antibody molecule when expressed in the cell line CHOdhfr− [ATCC No. 
CRL-9096 (CHOdhfr-); i/ili - ima povećanu staničnu citotoksičnost vezanu uz Fc, koja je najmanje 2 puta veća od stanične citotoksičnosti vezane uz Fc pripravka s najmanje jednom molekulom protutijela za istu molekulu protutijela kada se eksprimira u staničnoj liniji ATCC No.
Furthermore, the particular manufacturing method of currently commercially available therapeutic hosiery items requires, in order to produce the heel and/or toe regions, alternating rotary actuation of the needle cylinder about its axis, with relatively long production times and accordingly with relatively high production costs. 
Osim toga, kod izrade sada komercijalno dostupnih terapeutskih čarapa, da bi se proizvelo područja pete i/ili nožnih prstiju, poseban postupak zahtjeva naizmjenično rotacijsko pokretanje cilindra s iglama oko njegove osi, s relativno dugim vremenom proizvodnje i s tim u skladu s relativno visokim troškovima proizvodnje.
Doses of this range were successfully used in previous trials (Brunsvig et al 2006; Staehler et al 2007). Another aspect of the present invention includes an in vitro method for producing activated T cells, the method comprising contacting T-cells in vitro with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate the T-cell in an antigen specific manner, wherein the antigen is a peptide according to the invention. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I ili II s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen ili umjetnog spoja koji oponaša stanicu koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s bilo kojim patentnim zahtjevom od 1 do 2.
The liquefied gas treatment system according to claim 1, wherein the main BOG supply line includes a heat exchanger configured to liquefy BOG, which is not supplied to the main engine and the sub engine among BOG compressed by the compressor, by exchanging heat with BOG that is discharged from the cargo tank and transferred to the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što kompresor uključuje prvi kompresor (13a) i drugi kompresor (13b), gdje se prva struja se grana u drugu struju i treću struju nakon prolaska kroz prvi kompresor.
The pyridone derivative, or a salt thereof, according to any of claims 1 to 3, wherein R2 in the formula (I) represents a hydrogen atom, a halogen atom, a C1-C6 alkoxy group, or a C1-C6 alkyl group. 
Derivat piridona ili njegova sol prema patentnim zahtjevima 1 do 3, naznačen time da je R2 u formuli (I) atom vodika, atom halogena, C1-C6 alkoksi grupa,ili C1-C6 alkil grupa.
an armored skin configured about said fuel tank. 
oklopnu oplatu, konfiguriranu oko navedenog spremnika goriva.
In the finely divided particulate form of the medicament, and in the aerosol composition where the active ingredient is present in particulate form, the active ingredient may have an average particle diameter of up to 4 um. 
U lijeku koji je u obliku fino razdijeljenih čestica i u sastavu aerosola gdje je djelatna tvar prisutna u obliku čestica, djelatni sastojak može imati prosječni promjer čestica do 4 um.
treating the compound of Formula III with an organometallic compound of Formula IV: 
HR P20130862 T1 i tretiranja spoja Formule IIIb s organometalnim spojem Formule IV:
The package includes a lightweight frame for storing the disc, and the frame is encompassed by a sheath, which is securely bonded to an exterior surface of the frame. 
Pakiranje uključuje lagani okvir za pohranjivanje diska, a okvir je sastavljen od korica koje su čvrsto povezane s vanjskom površinom okvira.
The methylene chloride solution was washed with saturated sodium carbonate solution (200 ml), dried (MgS04), filtered and evaporated to dryness. 
Metilenkloridna otopina se ispere sa zaštićenom otopinom natrij-karbonata (200 ml), suši se (MgSO;y), filtrira i ispari do suhog.
In the present invention, the CFA compound having a CaO/Al2O3 molar ratio of 0.15 to 0.7 and a Fe2O3 content of 0.5 to 20% may be used in combination with the potentially hydraulic substance and/or pozzolan substance for the purpose of maintaining sufficient rustproofness, resistance to penetration of chloride ions and the effect on keeping Ca ions from leaching, enhancing initial strength, and improving the self-recovery capability. 
Cementna primjesa, koja sadrži kalcijev feroaluminatni spoj, te potencijalno hidrauličnu tvar i/ili pucolansku tvar, naznačena time što navedeni kalcijev feroaluminatni spoj sadrži sustav CaO-AbO3-Fe,0, i ima sadržaj Fe203 koji se kreće od 0,5 do 15%, maseno, i strukturu CaO * 2AbO; s molarnim omjerom CaO/AbO> koji se kreće od 0,15 do 0,7.
A leveling spacer (10) for laying wall tiles (P1, P2), paving tiles and the like with the interposition of gaps, characterized in that it comprises 
PATENTNI ZAHTJEVI Umetak za niveliranje (10) za polaganje zidnih pločica (P1, P2), podnih obloga 1 sličnoga, u svrhu osiguravanja razmaka, koji obuhvaća:
"Divalent C3-C8-cycloaliphatic" denotes cycloalkylene having 3- to 8-ring carbon atoms, e.g., a monocyclic group, such as a cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene or cyclooctylene, any of which can be substituted by one or more, usually one or two, C1-C4-alkyl groups; or a bicyclic group, such as bicycloheptylene or bicyclooctylene. 
"Dvovalentan C;-Czg-cikloalifatski" označava ciklo-alkilen koji ima 3 do 8 ugljikovih atoma u prstenu, npr. monocikličku skupinu, kao što je ciklopropilen, ciklobutilen, ciklopentilen, cikloheksilen, cikloheptilen ili ciklooctilen, od kojih svaka može biti supstituirana s jednom ili više, obično s jednom ili dvije C,-Cx-alkilne skupine; ili bicikličku skupinu, kao što je bicikloheptilen ili biciklooktilen. Ponajprije "C;-Cy-cikloalkilen" je C;-Cs-cikloalkilen, npr. ciklopropilen, ciklobutilen ili ciklopentilen.
dissolving at least a part of at least one of said precipitated phosphate compounds and said precipitated aluminium phosphate by an alkaline solution into a second leach solution; 
otapanje (302) barem dijela barem jednog od spomenutih istaloženih fosfatnih spojeva i spomenutog istaloženog aluminij fosfata alkalnim otapalom u drugu otopinu za ispiranje;
In one aspect, R23 is a straight or branched aliphatic carbon chain of 1 to 6, 1 to 5, 1 to 4, 1 to 3 or 2 carbons in length. 
(e) je ravan ili razgranat alifatni lanac ugljika duljine od 1 do 6, 1 do 5, 1 do 4, 1 do 3 ili 2 ugljika.
Computer readable medium, comprising a computer program product according to claim 9. 
Medij koji računalo može očitati, sadrži proizvod računalnog programa prema zahtjevu 9.
forming a salt of the compound prepared in any of steps (a) to (e). 
U opcionalnom koraku (e), nastaje sol spoja iz prvog aspekta .
obtaining a yarn of cellulosic filaments or fibres; chemically modifying the yarn to give the yarn gel forming properties, wherein the chemically modified yarn has a dry tensile strength of at least about 400 cN, the yarn capable of being converted into a fabric by knitting. 
(ii) predenje ili uvijanje celuloznih vlakana ili filamenta tako da nastane pređa; (ili) kemijsko modificiranje pređe da se dobije pređa sa svojstvima formiranja gela; pri čemu pređa ima linearnu gustoću od 20 tex do 40 tex.
The inside front wall 7 features two extrusion ridges 10 and 11 oriented towards the box interior. 
Unutarnji prednji zid 7 sadrži dva udubljena ruba 10 i 11 usmjerena prema unutrašnjosti kutije.
The system of aspect 1 wherein the electrically resistive material comprises metallic wire, trace, flakes, foil, or film. 
Sustav (10) prema zahtjevu 1, pri čemu električno otporni materijal obuhvaća metalnu žicu, tragove, krhotine, foliju ili film.
The binding molecule according to claim 1, comprising one or more polypeptide sequences selected from the group consisting of SEQ ID NO: 4 (IgG1 heavy), SEQ ID NO: 5 (IgG1 light), SEQ ID NO: 24 (IgG4 heavy) and SEQ ID NO: 25 (IgG4 light). 
Vezna molekula prema zahtjevu 1, naznačena time, da obuhvaća jednu ili više polipeptidnih sekvenci odabranih iz skupine koju čine: SEQ ID NO: 4 (IgG1, jaki lanac), SEQ ID NO: 5 (IgG1, slabi lanac), SEQ ID NO: 24 (IgG4, jaki lanac) i SEQ ID NO: 25 (IgG4, slabi lanac).
A product comprising a recombinant human follicle stimulating hormone (FSH) for use in the treatment of infertility in a patient having serum AMH level of < 15 pmol/L, wherein the product is to be administered at a dose of, or equivalent to, 11-13 µg recombinant human FSH per day, wherein the product further comprises hCG. 
Proizvod koji sadrži rekombinantni ljudski folikulostimulirajući hormon (FSH) za upotrebu u liječenju neplodnosti kod pacijenta koji ima razinu seruma AMH <15 pmol/L., naznačen time da se proizvod daje u dozi, ili ekvivalentnoj od, 11-13 ug rekombinantnog ljudskog FSH dnevno, zajedno s antagonistom GnRH.
The organic phase is washed (3x50 ml) with a buffer solution pH=4.2, dried over Na2SO4, filtered and concentrated under vacuum to obtain a yellow oil. 
Organska faza je prana (3 X 50 mL) s pufer otopinom pH = 4.2, sušena izand Na,SO4, filtrirana i uparena pod vakuumom i dobiveno je žuto ulje.
A method of producing a beverage containing less than 20 ppb DMS, said method comprising the steps of: 
Postupak proizvodnje pića koje sadrži manje od 20 ppb DMS i manje od 20 ppb SMM, navedeni postupak sadrži korake:
The composition of claim 1, wherein the CTLA4-Ig molecules are less than or equal to 0.5 area percent high molecular weight species as determined by size exclusion chromatography and spectrophotometric detection. 
Pripravak prema zahtjevu 1, gdje su CTILA4-Ig molekule manje ili jednake 0.5 posto površine od vrsta visoke molekulske težine kako je određeno kromatografijom isključenja po veličini i spektrofotometrijskim otkrivanjem.
In more preferred embodiments, the polyreactive, low-avidity autoantibodies are of the human IgG isotype. In some embodiments, the biological sample is diluted at least 1,000 fold or at least 5,000 fold with a low conductivity dilution buffer prior to step (a). 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je biološki uzorak razrijeđen najmanje 1000 puta ili najmanje 5000 puta niskovodljivim puferom za razrjeđivanje prije koraka (a).
The compound or a pharmacologically acceptable salt thereof according to claim 5, wherein R1 is a group represented by the following general formula (4): wherein R4 and R25 are as defined for R4 and R25 in claim 5. 
Spoj, ili njegova farmakološki prihvatljiva sol, u skladu s patentnim zahtjevom 5, naznačen time što je R1 skupina prikazana sljedećom općom formulom (4): [image], gdje su R4 i R25 definirani kao za R4 i R25 u patentnom zahtjevu 5.
The resulting dark-residue was stirred with 0.5 M Na2CO3 (150 mL) for 30 min and extracted with EtOAc (3×50 mL). 
Dobiveni tamni ostatak je miješan sa 0.5 M NaCO; (150 mL) 30 minuta i ekstrahiran sa EtOAc (3 X 50 mL).
In another embodiment of the methods of the invention, the buffer is selected from the group consisting of BIS-TRIS, BIS-TRIS Propane, HEPES, HEPES Sodium Salt, MES, MES Sodium salt, MOPS, MOPS sodium salt, sodium salt or sodium phosphate buffer (monobasic, tribasic PO4). 
Reagens prema zahtjevu 1, naznačen time da pufer je odabran iz skupine koja sadrži monobazični kalijev fosfat i trobazični kalijev fosfat, BIS-TRIS, BIS-TRIS propan, HEPES, HEPES natrijevu sol, MES, MES natrijevu sol, MOPS, MOPS natrijevu sol, natrijevu sol, i natrijev fosfatni pufer.
The solid oral extended release pharmaceutical dosage form of any one of items 84 and 85, wherein the extended release matrix formulation has a cracking force of at least about 120 N, at least about 130 N or at least about 140 N and/or a "penetration depth to crack" distance of at least about 1.2 mm, preferably of at least about 1.4 mm, at least about 1.5 mm or at least about 1.6 mm. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, naznačen time da, formulacija matrice s produljenim otpuštanjem ima snagu pucanja od barem oko 120 N, od barem oko 130 N ili od barem oko 140 N i/ili,,dubinu prodiranja s razmakom pukotine" od barem oko 1.2 mm, poželjno od barem oko 1.4 mm, od barem oko 1.5 mm ili od barem oko 1.6 mm.
An intermediate of formula (II): wherein LG1 represents halo; and X, R3a, R3b, R4 and R5 are as defined in claim 1. 
Intermedijer sa formulom (II): [image] naznačen time da LG1 predstavlja halo; i X, R3a, R3b, R4 i R5 su kako je definirano u zahtjevu 1.
The bispecific fusion protein according to claim 9, wherein LAG-3 is human LAG-3 comprising at least one of mutations R73E, R75A, R75E and R76E. 
Bispecifični fuzijski protein prema zahtjevu 8, naznačen time što LAG-3 je ljudski LAG-3 koji sadrži barem jednu od mutacija R73E, R75A, R75E i R76E, poželjno R75A ili R75E.
reacting Compound (L) with a C1-6 alkoxide to form Compound (M) 
(3) reakciji Spoja (L) s Ci.s alkoksidom kako bi se dobilo Spoj (M)
The composition of the processing fluid comprises 1 to 5 wt% of the long chain primary amine, 1 to 5 wt% of the tertiary cycloalkylamine, 1 to 5 wt% of the amino acid, 1 to 50 wt% of water, and a 100 wt% balancing amount of the petroleum-based or non-petroleum-based oil. In some embodiments of the processing fluid, it includes the petroleum-based oil. In other embodiments of the processing fluid, it includes the non-petroleum-based oil. 
Tekućina za obradu naznačena time što sadrži: 100 mas.% ravnotežne količinu ulja na bazi nafte ili ulja koje nije na bazi nafte; 1 do 50 mas.% vode; 1 do 5 mas.% dugolančanog primarnog amina, pri čemu dugolančani primarni amin je Cg-C24 primarni amin; 1 do 5 mas.% etoksiliranog tercijarnog cikloalkilamina; 1 1 do 5 mas.% aminokiseline; pri čemu tekućina za obradu je bez bora uz udio manje od 0.5 mas.% bora 1 bez sekundarnog amina uz udio manje od 0.5 mas.% sekundarnog amina.
The apparatus according to claim 2, wherein the fixation device, when implanted in a patient with the combined device, is adapted to attach together portions of the stomach wall so at to invaginate the combined device from outside of the patient's stomach wall. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je uređaj prilagođen da bude u najmanju ruku djelomično invaginiran u stijenku želuca međuželučanim kopčama, s vanjske strane stijenke želuca.
imidazolidinyl optionally substituted with methyl 
-C3 alkilom po izboru supstituiran s
The terminal according to claim 1 wherein DVRBs with non-consecutive DVRB numbers are mapped to PRBs, which are adjacent to each other in the frequency domain. 
Integrirani krug sukladno jednom od zahtjeva 1 do 13, naznačen time da su DVRB-i s ne-uzastopnim DVRB brojevima mapirani na dva od PRB-a koji su susjedni u frekvencijskoj domeni.
repeating steps (b) and (c) until at least 90% of the protein component is incorporated into lipoprotein complexes, thereby forming lipoprotein complexes. 
Postupak prema zahtjevu 1, naznačen time što se koraci (b) i (c) ponavljaju sve dok se najmanje 85%, najmanje 90%, ili najmanje 95% proteinske komponente je ugrađeno u lipoproteinske komplekse.
wherein the affinity of the antibody in its bivalent form to human CD79b is substantially the same as or at least 2, 3, 4, 5, 6, 7, 8, 9 or 10-fold greater than the affinity of a murine or chimeric antibody comprising a light chain and heavy chain variable sequence of SEQ ID NO: 10 and SEQ ID NO: 14 in its bivalent form, wherein the binding affinity is expressed as a Kd value, and wherein the binding affinity is measured by Biacore. The antibody of claim 1 or claim 2, which binds to the same epitope as a monoclonal antibody comprising the variable domains of SEQ ID No:10 and SEQ ID No:14. 
HVR-H3 koja sadrži sekvencu F1-F10, gdje F1-F10 je TRRVPIRLDY (SEQ ID NO: 204); pri čemu se protutijelo veže na isti epitop kao i monoklonalno protutijelo koje sadrži varijabilne domene od SEQ ID No. 10 i SEQ ID No. 14, protutijelo koje sadrži varijabilne domene od SEQ ID No. 207 i SEQ ID No. 208 ili protutijelo koje sadrži sekvencu slabog lanca od SEQ ID No. 307 i sekvencu jakog lanca od SEQ ID No. 308.
The method of claim 3, wherein the cancer is a lung cancer, brain cancer, central nervous system cancer, colon cancer, prostate cancer, renal cancer, head and neck cancer, ovarian cancer, uterine cancer, bladder cancer, breast cancer, pancreatic cancer, acute myeloid leukemia, acute lymphoblastic leukemia, myeloma, pediatric cancer or a resistant cancer. 
Farmaceutski sastav za uporabu iz patentnog zahtjeva 10, pri čemu je rak odabran iz grupe koja se sastoji: raka pluća, raka mozga ili središnjeg živčanog sustava, raka kolona, raka prostate, raka bubrega, metastatskog melanoma, raka glave i vrata, raka jajnika, raka maternice, akutne mijeloične leukemije, akutne limfoblastične leukemije, mijeloma i pedijatrijskih maligniteta.
The invention relates to pharmaceutical compositions for the treatment of multiple sclerosis which comprises a zinc-hyaluronan complex as active ingredient and a pharmaceutically acceptable carrier and/or additive. 
Izum se odnosi na farmaceutske sastave za liječenje multiple skleroze, koji sadrže cink-hijaluronski kompleks kao aktivnu tvar i farmaceutski prikladan nosač i/ili dodatak.
, R2 and R3 are independently selected from the group consisting of hydrogen, CO R 4, C(=O)O R4 and C(=O)CH R5 NH R6; or R1 and R3 are H and R2 is the monophosphate, diphosphate or triphosphate ester; 
, R2 i R3 nezavisno su izabrani iz grupe koju čine vodik, COR4, C(=O)OR4 i C(=O)CHR5NHR6; ili R1 i R3 su H i R2 je monofosfatni, difosfatni ili trifosfatni ester;
A compound as claimed in claim 14 where the purine nucleoside phosphorylase is human purine nucleoside phosphorylase (Hs PNP) or from the protozoan parasite Plasmodium falciparum (Pf PNP). 
Upotreba spoja prema bilo kojem od zahtjeva 12 do 14 naznačena time da purinska nukleozidna fosforilaza je humana purinska nukleozidna fosforilaza (Hs PNP) ili Plasmodium falciparum purinska nukleozidna fosforilaza (Pf PNP).
The IL-17 inflammatory response may be local or systemic. Examples of diseases and conditions that may be mediated by IL-17 or the Th17 pathway include uveitis; cancer, such as breast cancer, lung cancer, liver cancer, colon cancer, or ovarian cancer; multiple sclerosis; arthritis, such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvenile idiopathic arthritis; neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; inflammatory bowel disease, such as Crohn's disease or ulcerative colitis; celiac disease; asthma, such as allergic asthma or neutrophilic asthma; chronic obstructive pulmonary disease (COPD); scleritis; vasculitis; Behcet's disease; atherosclerosis; atopic dermatitis; emphysema; periodontitis; allergic rhinitis; and allograft rejection. 
Pripravak prema zahtjevu 1, naznačen time da je pripravak za upotrebu u postupku liječenja ili prevencije bolesti ili stanja koje se biraju iz skupine koja sadrži uveitis; rak, kao što je rak dojke, rak pluća, rak jetre, rak debelog crijeva, ili rak jajnika; multiple skleroza; artritis, kao što je reumatoidni artritis, osteoartritis, psorijazni artritis, ili juvenilni idiopatski artritis; neuromijelitis optika (Devicova bolest); ankilozirajući spondilitis; spondiloartritis; psorijaza; sistemski eritemski lupus; upalna bolest crijeva, kao što je Crohnova bolest ili ulcerativni kolitis; celijakija; astma, kao što je alergijska astma ili astma koja je posredovana neutrofilima; kronična opstruktivna plućna bolest (KOPB); skleritis; vaskulitis; Behcetova bolest; ateroskleroza; atopijski dermatitis; emfizem; periodontitis; alergijski rinitis; te odbacivanje alografta.
Pharmaceutical dosage form according to claim 4 in form of a soft gelatin capsule containing 125 mg of active substance free base equivalent, selected from the following compositions A, B and C: 
Farmaceutski dozni oblik prema zahtjevu 4, naznačen time, da je u obliku mekane želatinske kapsule koja sadrži 125 mg djelatne tvari, ekvivalenta slobodne baze, koji je odabran od sljedećih sastava A, B i C:
The method according to claim 2, wherein the compound Cu2SO3.CuSO3.2H2O is applied using foliar application in the amount in the range of 10 to 1500 g/ha, preferably 25 to 500 g/ha, more preferably 50 to 250 g/ha. 
3. Postupak prema patentnom zahtjevu 2 naznačen time da se spoj Cu,SO3.CuSO3.210 nanosi folijarnom primjenom u količini u opsegu od 10 do 1500 g/ha, poželjno 25 do 500 g/ha, najpoželjnije 50 do 250 g/ha.